Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
– NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at
Nektar Therapeutics to Participate in Upcoming Investor Conferences
06:00pm, Wednesday, 06'th Nov 2024
SAN FRANCISCO , Nov. 6, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global Healthcare
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
01:44pm, Monday, 04'th Nov 2024
Piper Sandler has initiated coverage on Nektar Therapeutics Inc NKTR, citing the company's lead asset rezpegaldesleukin's (REZPEG) differentiated mechanism of action.
Huntsville-based facility to be spun out as standalone Ampersand portfolio company. Nektar to receive $90 million in total consideration for the business, comprised of $70 million in cash and $20 mill
SAN FRANCISCO , Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-b
- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes - - Biomarker
– Relapse-free/progression-free survival for NKTR-255 plus CD19-22 CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) – – Eight of nine patients achieved comple
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
03:30am, Wednesday, 25'th Sep 2024
- New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing specific serum proteins known to be elevated in patients with atopic derm
Nektar Management to Present at Upcoming Investor Conferences
09:00am, Tuesday, 03'rd Sep 2024
SAN FRANCISCO , Sept. 3, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: H.C.
What Makes Nektar (NKTR) a New Buy Stock
01:00pm, Tuesday, 13'th Aug 2024
Nektar (NKTR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript
09:04am, Saturday, 10'th Aug 2024
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
12:00pm, Friday, 09'th Aug 2024
Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
06:56pm, Thursday, 08'th Aug 2024
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.27 per share a year ago.
Nektar Therapeutics Reports Second Quarter 2024 Financial Results
04:15pm, Thursday, 08'th Aug 2024
SAN FRANCISCO , Aug. 8, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2024. Cash and investments in marketable securiti
SAN FRANCISCO , Aug. 1, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2024 on Thursday, August 8, 2024, after the close of U.S.-bas
